- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06412510
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Prehabilitation for Elderly Patients With Advanced Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Mariam AlHilli, MD
- Phone Number: 216-644-0418
- Email: alhillm@ccf.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
-
Contact:
- Mariam AlHilli, MD
-
Principal Investigator:
- Mariam AlHilli, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 65 and older
- Patients with diagnosis of advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (EOC) undergoing neoadjuvant chemotherapy; OR Patients with diagnosis of pancreatic adenocarcinoma undergoing neoadjuvant chemotherapy
Exclusion Criteria:
- Life expectancy less than 3 months in the opinion of the treating physician
- Patients unable to provide informed consent.
- Wheelchair bound patients/ physical immobility.
- Severe cardiopulmonary disease defined as NYHA class III or IV
- Patients with malignant bowel obstruction who will require surgical intervention or nutritional support in the form of enteral or parenteral nutrition will also be excluded.
- Patients with any other comorbidity or condition, which, in the opinion of the enrolling investigator, would place the patient at unnecessarily higher greater risk or burden, or participating in the study would not be in the best interests of the patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention - Arm 1
Exercise Intervention: Participants will be referred to Langston Hughes Community Center and work with exercise physiologists who will utilize our SmartGym ecosystem in providing exercise assessments, prescriptions, and training. Nitrition Intervention: Participants in the intervention group will be provided with 1-2 bottles of high protein oral nutritional supplements daily (ONS) to ensure that protein needs are met daily. There will be two options of ONS to choose from: one option a high calorie, high protein supplement, and the other option a low fat/low sugar, high protein supplement. Supportive care/Mind-body intervention: Participants will have access to Taussig Cancer Institute Patient Support services that are offered for free. |
Exercise Intervention: SmartGyms, band or smartphone used to scan into the TechnoGym MyWellness kiosk, which controls the TechnoGym Excite Live and Biostrength equipment. The exercise session will consist of a program that adheres to the FITT (Frequency, Intensity, Timing, and Type) exercise prescription in accordance with ACSM 2018 ACSM Roundtable recommendations for Physical Function for combined Aerobic and Resistance training. Nutrition Intervention: 30 gm protein supplement Supportive care/Mind-body intervention: Yoga, mindfulness practices, art therapy, and music therapy |
No Intervention: Control - Arm 2
Exercise: Standard of care. Level of activity will be reported and monitored at each visit through study coordinator assessment and patient interview. Nutrition: Participants will be referred to dietitian and will be seen for a baseline evaluation, as needed throughout treatment and post treatment. A full nutrition assessment will be performed, and malnutrition diagnosis will be documented. When no malnutrition is identified participants will be provided general nutrition counseling related to their cancer type, cancer treatment, and recommendations for symptom management as needed. Those participants identified to be malnourished to any degree will receive personalized medical nutrition therapy including nutrition interventions to improve caloric intake. Supportive care/Mind-body intervention: Per standard of care, participants will be offered support services from Taussig Cancer Institute program. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of adherence as calculated by the compliance percentage
Time Frame: 6 weeks post intervention
|
Compliance will be defined as completion of at least 2 exercise sessions per week (75%) for the duration of the study.
|
6 weeks post intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in effectiveness of prehabilitation as assessed by 1 Rep Max Isokinetic strength test
Time Frame: Baseline, 6 weeks post intervention
|
Rep Max Isokinetic Strength Test measured by BiostrengthTM Maximal Strength
|
Baseline, 6 weeks post intervention
|
Change in effectiveness of prehabilitation as assessed by Grade Exercise Test Grade Exercise Test measured by Grade Exercise Test.
Time Frame: Baseline, 6 weeks post intervention
|
At baseline, and within the immediate post-exercise recovery, rating of perceived exertion (RPE; Borg scale, 6-20) will be assessed. Peak exercise exhaustion was verified if two or more of the following criteria were met: 1)96 HR within 10 bpm of age-predicted maximum HR (220-age), 2) RPE > 17, and/or 3) a plateau in HR (<3 bpm change over the last two intensity stages). VO2 max will be calculated by ACSM's Treadmill Walking Equation: VO2 [ml/kg/min] = (0.1 x speed) + (1.8 x Speed x Grade) 3.5 ml/kg/min |
Baseline, 6 weeks post intervention
|
Change in effectiveness of prehabilitation as assessed by timed up and go test
Time Frame: Baseline, 6 weeks post intervention
|
Timed up and go test is one unit of time to measure how fast patients can move
|
Baseline, 6 weeks post intervention
|
Change in effectiveness of prehabilitation as assessed by 6-minute walk test
Time Frame: Baseline, 6 weeks post intervention
|
The 6-minute walk test is measured by the distance walked in 6 minutes
|
Baseline, 6 weeks post intervention
|
Change in effectiveness of prehabilitation as assessed by grip strength test
Time Frame: Baseline, 6 weeks post intervention
|
Grip strength test measured by handheld dynamometer
|
Baseline, 6 weeks post intervention
|
Change in effectiveness of prehabilitation as assessed by 30 second sit to stand test
Time Frame: Baseline, 6 weeks post intervention
|
The number of times a patient can rise to a standing position from a seated position without the use of their upper extremities is counted in a thirty second period.
|
Baseline, 6 weeks post intervention
|
Change in measure of balance as assessed by unipedal stance test
Time Frame: Baseline, 6 weeks post intervention
|
This is a measure of balance and is assessed by asking the participant to stand on one foot (of their choice) with the lifted foot remaining close to their opposite ankle, first with eyes open and then with eyes closed.The amount of time a participant can stand on one foot is recorded.
|
Baseline, 6 weeks post intervention
|
Effectiveness of prehabilitation as assessed by measuring the change in body mass composition
Time Frame: Baseline, 6 weeks post-intervention
|
Body composition measured using contrast-enhanced CT scan
|
Baseline, 6 weeks post-intervention
|
Effectiveness of prehabilitation as assessed by the change in nutritional status
Time Frame: Baseline, Cycle 2 day 1, cycle 3 day 1, cycle 4 day 1(each cycle is 21 days) and 6 weeks post-intervention
|
Assessed for the presence of malnutrition per the Cleveland Clinic organization's standard of care based on American Society for Parenteral and Enteral Nutrition (ASPEN) and the Academy of Nutrition and Dietetics (AND) (ASPEN/AND) guidelines, and by assessing changes in the degree of malnutrition throughout the study period
|
Baseline, Cycle 2 day 1, cycle 3 day 1, cycle 4 day 1(each cycle is 21 days) and 6 weeks post-intervention
|
Quality of life as assessed by FACT-G7 (Functional Assessment of Cancer Therapy)
Time Frame: At baseline
|
Functional Assessment of Cancer Therapy(FACT-G7) to assess the illness is measured on a scale from 0 to 4, where 0 is 'not at all' and 4 is 'very much'
|
At baseline
|
Quality of life as assessed by FACT-G7 (Functional Assessment of Cancer Therapy)
Time Frame: Upto 6 weeks post intervention
|
Functional Assessment of Cancer Therapy(FACT-G7) to assess the illness is measured on a scale from 0 to 4, where 0 is 'not at all' and 4 is 'very much'
|
Upto 6 weeks post intervention
|
Quality of life as assessed by FACT-O
Time Frame: At baseline
|
FACT-O to assess the illness is measured on a scale from 0 to 4, where 0 is 'not at all' and 4 is 'very much'
|
At baseline
|
Quality of life as assessed by FACT-O
Time Frame: Upto 6 weeks post intervention
|
FACT-O to assess the illness is measured on a scale from 0 to 4, where 0 is 'not at all' and 4 is 'very much'
|
Upto 6 weeks post intervention
|
Effectiveness of prehabilitation as assessed by Chemotherapy toxicity
Time Frame: At cycle 2, day 1(each cycle is 21 days)
|
Chemotherapy toxicity as measured by the standard CTCAE v5 grading system
|
At cycle 2, day 1(each cycle is 21 days)
|
Effectiveness of prehabilitation as assessed by Chemotherapy toxicity
Time Frame: At cycle 3, day 1(each cycle is 21 days)
|
Chemotherapy toxicity as measured by the standard CTCAE v5 grading system
|
At cycle 3, day 1(each cycle is 21 days)
|
Effectiveness of prehabilitation as assessed by Chemotherapy toxicity
Time Frame: At cycle 4, day 1(each cycle is 21 days)
|
Chemotherapy toxicity as measured by the standard CTCAE v5 grading system
|
At cycle 4, day 1(each cycle is 21 days)
|
Effectiveness of prehabilitation as assessed by Chemotherapy toxicity
Time Frame: Upto 6 weeks post intervention
|
Chemotherapy toxicity as measured by the standard CTCAE v5 grading system
|
Upto 6 weeks post intervention
|
Effectiveness of prehabilitation as assessed by participant acceptability of intervention survey using IAM(Intervention appropriateness measure)
Time Frame: Upto 6 weeks post intervention
|
IAM is measured on a scale of 1 to 5, where 1 is completely disagree and 5 is completely agree.
|
Upto 6 weeks post intervention
|
Effectiveness of prehabilitation as assessed by participant acceptability of intervention survey using FIM(Feasibility of intervention measure)
Time Frame: Upto 6 weeks post surgery
|
FIM is measured on a scale of 1 to 5, where 1 is completely disagree and 5 is completely agree.
|
Upto 6 weeks post surgery
|
Effectiveness of prehabilitation as assessed by participant acceptability scale
Time Frame: Baseline
|
Participant acceptability of anxiety and depression screening as measured by Hospital anxiety and depression scale(HADS) scoring from 0-21 where 0-7 is normal;8-10 is borderline abnormal; 11-21 is abnormal
|
Baseline
|
Effectiveness of prehabilitation as assessed by participant acceptability scale
Time Frame: Upto 6 weeks post surgery
|
Participant acceptability of anxiety and depression screening as measured by Hospital anxiety and depression scale(HADS) scoring from 0-21 where 0-7 is normal;8-10 is borderline abnormal; 11-21 is abnormal
|
Upto 6 weeks post surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mariam AlHilli, MD, Cleveland Clinic Foundation, Case Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
- CASE3824
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Adenocarcinoma
-
Fudan UniversityUnknownStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Scandion Oncology A/SAlcedis GmbHRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Inoperable Disease | Localized Pancreatic AdenocarcinomaDenmark, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Jean-Luc Van LaethemCelgene CorporationCompletedPancreatic Adenocarcinoma Resectable | Pancreatic Adenocarcinoma Metastatic | Pancreatic Adenocarcinoma Locally AdvancedBelgium
Clinical Trials on Prehabilitation
-
Stanford UniversityCompletedSurgery | Thoracic Diseases | Gastrointestinal Disease | Preoperative Care | Gynecologic Disease | Immune System and Related Disorders | Urological DiseaseUnited States
-
Mount Sinai Hospital, CanadaUniversity Health Network, TorontoUnknownPhysical Activity | Surgery | Gastrointestinal Cancer | PrehabilitationCanada
-
Istituto Ortopedico GaleazziMinistry of Health, ItalyRecruiting
-
Belfast Health and Social Care TrustQueen's University, BelfastRecruitingLiver TransplantUnited Kingdom
-
Vestre Viken Hospital TrustDiakonhjemmet HospitalNot yet recruitingFrailty | Surgery | Cancer Colorectal
-
Universitat Jaume IRecruitingCancer of Colon | Prehabilitation | Cancer of Rectum | Cancer, OvarianSpain
-
Dr. Todd A DuhamelRecruitingFrailty | Cardiac Surgery | Telerehabilitation | Prehabilitation | Pre-operative ExerciseCanada
-
Jessa HospitalNot yet recruitingGynecologic Cancer | Prostate Cancer
-
University of CalgaryAlberta Cancer FoundationNot yet recruitingLeukemia
-
Associacao de Investigacao de Cuidados de Suporte...Centro Hospitalar de Vila Nova de Gaia/Espinho; Aveiro University; University... and other collaboratorsRecruitingHead and Neck NeoplasmsPortugal